A study of FL-261 imaging for cancer diagnosis
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a known or suspected cancer (like lung, colon, or head and neck cancer).
- You must agree to let researchers use a sample of your tumor that was already taken.
- You must be in good overall health.
- You cannot be pregnant or breastfeeding.
- You must be willing and able to follow the study’s procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new radioactive treatment for people with advanced solid tumors, such as certain lung, colon, head and neck, or bile duct cancers, that have stopped responding to standard treatments. The treatment targets a protein called c-MET found on cancer cells, aiming to deliver radiation directly to the tumor.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
This trial tests a new imaging agent (68Ga-FL-031) to see if it can help find and stage tumors in people with small cell lung cancer, breast cancer, nasopharyngeal cancer, or other cancers. The goal is to improve diagnosis and treatment planning.
This study tests a new imaging agent called FL-091 to see if it helps doctors find and stage cancers like head and neck, colorectal, or pancreatic cancer. You’ll get a PET scan that may give clearer pictures of tumors.
This study tests a new type of imaging agent (called a tracer) that helps PET scans see tumors more clearly. It may help doctors find and monitor cancer better.
This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.